Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies if talazoparib works in patients with cancer that has spread to
other places in the body (advanced) and has mutation(s) in deoxyribonucleic acid (DNA) damage
response genes who have or have not already been treated with another PARP inhibitor.
Talazoparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP
may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP
inhibitors are a type of targeted therapy. All patients who take part on this study must have
a gene aberration that changes how their tumors are able to repair DNA. This trial may help
scientists learn whether some patients might benefit from taking different PARP inhibitors
"one after the other" and learn how talazoparib works in treating patients with advanced
cancer who have aberration in DNA repair genes.